CINECA IRIS Institutional Research Information System

LATROFA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 17.389
NA - Nord America 13.417
AS - Asia 4.767
SA - Sud America 965
Continente sconosciuto - Info sul continente non disponibili 373
AF - Africa 278
OC - Oceania 7
Totale 37.196
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.893
US - Stati Uniti d'America 10.808
CA - Canada 2.510
FI - Finlandia 1.998
SG - Singapore 1.468
CN - Cina 1.223
HK - Hong Kong 838
BR - Brasile 759
SE - Svezia 716
NL - Olanda 542
VN - Vietnam 487
DE - Germania 484
FR - Francia 354
BG - Bulgaria 269
GB - Regno Unito 262
AT - Austria 185
TR - Turchia 167
UA - Ucraina 151
RU - Federazione Russa 140
IN - India 121
JP - Giappone 100
CI - Costa d'Avorio 94
CH - Svizzera 63
AR - Argentina 61
SN - Senegal 59
PL - Polonia 55
KR - Corea 50
MX - Messico 49
ES - Italia 47
IQ - Iraq 43
BD - Bangladesh 42
ZA - Sudafrica 41
BE - Belgio 33
PY - Paraguay 31
EC - Ecuador 29
RO - Romania 28
ID - Indonesia 26
PK - Pakistan 24
CO - Colombia 22
LV - Lettonia 22
SA - Arabia Saudita 21
IE - Irlanda 20
VE - Venezuela 20
GR - Grecia 17
JO - Giordania 17
UZ - Uzbekistan 17
MA - Marocco 16
CL - Cile 15
EG - Egitto 15
DK - Danimarca 14
AL - Albania 12
CZ - Repubblica Ceca 12
PE - Perù 12
PH - Filippine 12
IL - Israele 11
JM - Giamaica 11
KZ - Kazakistan 11
ZM - Zambia 11
EE - Estonia 10
KE - Kenya 10
MY - Malesia 10
SM - San Marino 10
UY - Uruguay 10
AE - Emirati Arabi Uniti 9
TH - Thailandia 9
AZ - Azerbaigian 8
CR - Costa Rica 8
HU - Ungheria 8
PT - Portogallo 8
TW - Taiwan 8
AU - Australia 7
GT - Guatemala 7
HR - Croazia 7
IR - Iran 7
TN - Tunisia 7
ET - Etiopia 6
NP - Nepal 6
RS - Serbia 6
DO - Repubblica Dominicana 5
DZ - Algeria 5
LT - Lituania 5
MT - Malta 5
GE - Georgia 4
HN - Honduras 4
NG - Nigeria 4
OM - Oman 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BB - Barbados 3
BH - Bahrain 3
BO - Bolivia 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LY - Libia 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BW - Botswana 2
BY - Bielorussia 2
EU - Europa 2
KG - Kirghizistan 2
Totale 36.793
Salva come PNG Salva come JPEG
Città #
Montreal 2.335
Helsinki 1.897
Ashburn 1.104
Milan 945
Hong Kong 828
Dallas 820
Fairfield 767
Singapore 757
Woodbridge 746
Rome 688
San Jose 602
Ann Arbor 582
Santa Clara 561
Houston 503
Chandler 442
Seattle 329
Beijing 296
Florence 290
Naples 284
New York 271
Sofia 262
Shanghai 258
Wilmington 256
Cambridge 239
Serra 207
Council Bluffs 205
Bologna 166
Los Angeles 162
Vienna 157
Ho Chi Minh City 155
Boardman 149
Bari 144
Pisa 137
Princeton 121
Ottawa 119
Palermo 119
Turin 113
Lawrence 106
Hanoi 104
Munich 104
Lauterbourg 103
Medford 95
Abidjan 94
Catania 92
Brescia 83
Genoa 83
Tokyo 81
Hefei 78
London 70
Nanjing 67
Izmir 66
São Paulo 65
Des Moines 62
Dakar 59
Lucca 58
Padova 57
Dong Ket 56
Buffalo 54
Bremen 53
Redondo Beach 53
Vicopisano 53
Livorno 51
Cagliari 49
Frankfurt am Main 49
Verona 49
Seoul 47
Dearborn 44
Istanbul 43
San Diego 43
Atlanta 42
Orem 42
Jacksonville 37
Modena 37
Turku 37
Paris 36
Pescara 36
Redwood City 36
Bergamo 35
Marseille 34
Lancaster 32
Ogden 31
Guangzhou 30
Perugia 30
Chicago 29
Messina 29
Napoli 27
Rio de Janeiro 27
San Francisco 27
Boulder 26
Nanchang 26
Venice 26
Brooklyn 24
Reggio Emilia 24
Monza 23
Phoenix 23
Toronto 23
Ancona 22
Brussels 22
Caserta 22
Columbus 22
Totale 21.104
Salva come PNG Salva come JPEG
Nome #
Tiroidite cronica autoimmune 12.850
Ipotiroidismo subclinico 3.618
Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question 377
Thyroid imaging in the management of anti-PD1/PD-L1 induced thyrotoxicosis 360
Gozzo diffuso tossico (morbo di Flajani-Basedow-Graves) e tiroidite cronica autoimmune, Inquadramento nosologico e terapia medica 314
Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy 295
Spontaneous improvement of untreated mild graves' ophthalmopathy: Rundle's curve revisited. 257
Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy 250
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 245
Effects Of Long-term Tamoxifen Therapy On The Course Of Chronic Autoimmune Thyroiditis 240
Le malattie autoimmuni della tiroide 239
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 232
Management of thyrotoxicosis induced by PD1 or PD-L1 blockade 228
Diagnosi differenziale dell’oftalmopatia basedowiana 223
Role of the underlying thyroid disease on the phenotype of graves' orbitopathy in a tertiary referral center 221
Iodine contributes to thyroid autoimmunity in humans by unmasking a cryptic epitope on thyroglobulin. 217
Subacute thyroiditis after Sars-COV-2 infection 213
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 209
Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts 208
Causes and laboratory investigations of thyrotoxicosis 206
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 206
Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis 206
Is subacute thyroiditis an underestimated manifestation of SARS-CoV-2 infection? insights from a case series 206
Cytological and Ultrasound Features of Thyroid Nodules Correlate with Histotypes and Variants of Thyroid Carcinoma 201
Graves' Disease Induced by Immune Checkpoint Inhibitors: A case report and Review of the literature 200
Effect of thyroglobulin autoantibodies on the metabolic clearance of serum thyroglobulin 199
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 199
Significance of low levels of thyroglobulin autoantibodies associated with undetectable thyroglobulin after thyroidectomy for differentiated thyroid carcinoma 197
The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis 196
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial 195
VARIABLES AFFECTING THE LONG TERM OUTCOME OF GRAVES' ORBITOPATHY FOLLOWING HIGH DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY 193
Outcome of Graves' Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial 190
Thyroglobulin Autoantibodies arise before Thyroperoxidase Autoantibodies in Juvenile Autoimmune Thyroiditis 190
Compared with classic Hashimoto’s thyroiditis, chronic autoimmune serum‑negative thyroiditis requires a lower substitution dose of l‑thyroxine to correct hypothyroidism 190
Pathways to democratized healthcare: Envisioning human-centered AI-as-a-service for customized diagnosis and rehabilitation 189
The large majority of 1520 patients with indeterminate thyroid nodule at cytology have a favorable outcome, and a clinical risk score has a high negative predictive value for a more cumbersome cancer disease. 189
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 189
Diagnostic accuracy of a new fluoroenzyme immunoassay for the detection of TSH receptor autoantibodies in Graves' disease 189
Patients with indeterminate thyroid nodules at cytology and cancer at histology have a more favourable outcome with respect to patients with suspicious or malignant cytology 186
Circulating thyroglobulin transcytosed by thyroid cells is complexed with secretory components of its endocytic receptor megalin 185
Thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: comparison of different assays and evaluation of causes of discrepancies. 184
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases 183
Optic neuropathy in 2 thyroidectomized patients with moderate to severe Graves’ ophthalmopathy following L-thyroxine withdrawal prior to radioiodine treatment for thyroid carcinoma 181
Serum antibodies against megalin (gp330) in patients with autoimmune thyroiditis 180
Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine 180
Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy 180
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 179
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 178
Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology 178
Effect of thyroglobulin autoantibodies on the clearance of serum thyroglobulin in humans 178
Clinical features of thyroid autoimmunity are associated with thyroiditis on histology and are not predictive of malignancy in 570 patients with indeterminate nodules on cytology who had a thyroidectomy 177
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy 176
Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. 173
Human monoclonal thyroglobulin autoantibodies: epitopes and immunoglobulin genes. 172
Pathogenetic and clinical aspects of autoimmune thyroiditis 171
IgM thyroglobulin autoantibodies are detectable in serum of patients with subacute thyroiditis 168
In Graves' disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features 165
Thyroid volume and severity of graves' orbitopathy 163
Outcome of Graves’ Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial 161
Subacute Thyroiditis during the SARS-CoV-2 Pandemic 161
Activating Antibodies to the Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism 160
Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy 159
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 157
Intracellular retention of thyroglobulin in the absence of the low-density lipoprotein receptor-associated protein (RAP) is likely due to premature binding to megalin in the biosynthetic pathway 157
Evaluation of the Level of Thyroglobulin Autoantibodies Interfering with Thyroglobulin Measurement in Patients with Differentiated Thyroid Carcinoma 155
The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors 154
Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin. 153
COVID-induced thyroid autoimmunity 152
Rehabilitative orbital decompression for Graves' orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients' satisfaction 148
Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study 148
Hypothyroidism Due to L-T4 Withdrawal Can Precipitate Optic Neuropathy in Patients with Moderate to Severe Graves' Ophthalmopathy: Report on Two Cases 146
Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player? 146
Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade 145
Diffuse and Nodular Goiter 141
The detection of serum IgMs to thyroglobulin in subacute thyroiditis suggests a protective role of IgMs in thyroid autoimmunity 141
The detection of serum IgM to thyroglobulin in subacute thyroiditis suggests a protective role of IgM in thyroid autoimmunity 140
In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' orbitopathy 138
Clinical, biochemical features and functional outcome of patients with SARS-CoV-2-related subacute thyroiditis: a review 138
Diagnosi di laboratorio 134
Manifestaciones no oftalmológicas de la enfermedad de Graves 133
The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. 132
Serum levels of rapamycin predict the response of Graves' orbitopathy to sirolimus 130
Thyroglobulin Autoantibodies Switch to IgG1 and IgG3 Subclasses after 131I Treatment for Graves' Hyperthyroidism: Autoantibodies Subclasses Are Related to the Activity of Autoimmune Thyroid Disease 129
Un caso di MEN2B con anomalie scheletriche multiple 128
Thyroglobulin-thyroperoxidase autoantibodies are polyreactive, not bispecific: analysis using human monoclonal autoantibodies. 126
Late-onset dyshormonogenic goitrous hypothyroidism due to a homozygous mutation of the SLC26A7 gene: a case report 126
Iodine, thyroid autoimmunity and cancer 125
Thyroid stimulation does not require antibodies with identical epitopes but does involve recognition of a critical conformation at the N terminus of the thyrotropin receptor A-subunit. 123
Over hypothyroidism in a woman undergoing controlled ovarian hyperstimulation. 123
null 121
Evidence that the thyrotropin receptor protease is membrane-associated and is not within lipid rafts 121
Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis 121
null 120
Frequency of the GPR7 Tyr135Phe allelic variant in lean and obese subjects. 119
Low elasticity of thyroid nodules at ultrasound elastography is correlated with malignancy, degree of fibrosis and high expression of galectin-3 and fibronectin-1 119
Gozzo 112
Altre terapie dell’oftalmopatia basedowiana 112
Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy 112
Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. 111
Disappearance of Anti-Thyroid Autoantibodies following Thymectomy in Patients with Myasthenia Gravis 103
Totale 33.743
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.866
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.865 0 103 61 152 297 239 83 97 194 154 108 377
2022/20233.354 250 306 246 219 250 269 146 261 506 192 425 284
2023/20246.548 364 317 315 311 383 462 377 354 204 2.651 399 411
2024/20257.083 390 344 368 525 615 635 536 519 768 709 637 1.037
2025/20269.381 535 806 900 1.152 654 533 854 389 2.284 642 381 251
2026/20271.430 506 924 0 0 0 0 0 0 0 0 0 0
Totale 37.196